{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Observational+Phase+1&page=2", "query": { "intervention": "Observational Phase 1", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Observational+Phase+1&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-18T00:31:50.236Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02445391", "title": "Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Estrogen Receptor Negative", "HER2/Neu Negative", "Invasive Breast Carcinoma", "Progesterone Receptor Negative", "Stage II Breast Cancer", "Stage IIA Breast Cancer", "Stage IIB Breast Cancer", "Stage III Breast Cancer", "Stage IIIA Breast Cancer", "Stage IIIB Breast Cancer", "Stage IIIC Breast Cancer", "Triple-Negative Breast Carcinoma" ], "interventions": [ { "name": "Capecitabine", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ECOG-ACRIN Cancer Research Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 415, "start_date": "2015-10-20", "completion_date": "2031-03-29", "has_results": true, "last_update_posted_date": "2026-07-27", "last_synced_at": "2026-09-18T00:31:50.236Z", "location_count": 1023, "location_summary": "Mobile, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 634 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT02445391" }, { "nct_id": "NCT06270719", "title": "An Observational Study Comparing Delandistrogene Moxeparvovec (ELEVIDYS) With Standard of Care in Participants With Duchenne Muscular Dystrophy", "overall_status": "ENROLLING_BY_INVITATION", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Duchenne Muscular Dystrophy" ], "interventions": [ { "name": "Delandistrogene Moxeparvovec", "type": "GENETIC" }, { "name": "Standard of Care", "type": "DRUG" } ], "intervention_types": [ "GENETIC", "DRUG" ], "sponsor": "Sarepta Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "4 Years", "maximum_age": null, "sex": "MALE", "summary": "4 Years and older · Male only" }, "enrollment_count": 500, "start_date": "2024-02-07", "completion_date": "2038-12-31", "has_results": false, "last_update_posted_date": "2026-05-04", "last_synced_at": "2026-09-18T00:31:50.236Z", "location_count": 25, "location_summary": "Little Rock, Arkansas • Los Angeles, California • Aurora, Colorado + 22 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Hartford", "state": "Connecticut" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT06270719" }, { "nct_id": "NCT02707367", "title": "Recovery Roadmap Phase II Small Business Innovation Research Grant", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Mental Disorders", "Behavior Disorders" ], "interventions": [ { "name": "Recovery Roadmap (RR) Wave 1", "type": "BEHAVIORAL" }, { "name": "Recovery Roadmap (RR) Wave 2", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Center for Social Innovation, Massachusetts", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 127, "start_date": "2017-06-01", "completion_date": "2020-06-01", "has_results": false, "last_update_posted_date": "2020-10-01", "last_synced_at": "2026-09-18T00:31:50.236Z", "location_count": 1, "location_summary": "Needham, Massachusetts", "locations": [ { "city": "Needham", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02707367" }, { "nct_id": "NCT02392195", "title": "Brain Characteristics Noted Prior to and Following Treatment", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Nonsynostotic Plagiocephaly" ], "interventions": [ { "name": "Non-interventional", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Boston Children's Hospital", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": null, "maximum_age": "8 Months", "sex": "ALL", "summary": "Up to 8 Months" }, "enrollment_count": 10, "start_date": "2013-02", "completion_date": "2020-09", "has_results": true, "last_update_posted_date": "2020-12-10", "last_synced_at": "2026-09-18T00:31:50.236Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02392195" }, { "nct_id": "NCT00002657", "title": "SWOG-9239 Reduction of Immunosuppression Plus Interferon Alfa and Combination Chemotherapy in Treating Patients With Malignant Tumors That Develop After Organ Transplant", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm" ], "interventions": [ { "name": "bleomycin sulfate", "type": "BIOLOGICAL" }, { "name": "recombinant interferon alfa", "type": "BIOLOGICAL" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "cytarabine", "type": "DRUG" }, { "name": "doxorubicin hydrochloride", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "methotrexate", "type": "DRUG" }, { "name": "prednisone", "type": "DRUG" }, { "name": "vincristine sulfate", "type": "DRUG" }, { "name": "conventional surgery", "type": "PROCEDURE" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "15 Years", "maximum_age": null, "sex": "ALL", "summary": "15 Years and older" }, "enrollment_count": 20, "start_date": "1995-05", "completion_date": "2011-07", "has_results": false, "last_update_posted_date": "2013-01-24", "last_synced_at": "2026-09-18T00:31:50.236Z", "location_count": 86, "location_summary": "Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 54 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002657" }, { "nct_id": "NCT07804186", "title": "Study of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal Melanoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Uveal Melanoma" ], "interventions": [ { "name": "Darovasertib", "type": "DRUG" }, { "name": "Crizotinib (Xalkori)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "IDEAYA Biosciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 450, "start_date": "2026-09", "completion_date": "2034-04", "has_results": false, "last_update_posted_date": "2026-09-15", "last_synced_at": "2026-09-18T00:31:50.236Z", "location_count": 11, "location_summary": "Scottsdale, Arizona • Los Angeles, California • Boston, Massachusetts + 7 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT07804186" }, { "nct_id": "NCT05640102", "title": "Observational Study Evaluating the Efficacy and Safety of Zanubrutinib in Participants With Waldenström Macroglobulinemia", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Waldenstrom Macroglobulinemia" ], "interventions": [ { "name": "Zanubrutinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BeiGene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 111, "start_date": "2023-03-03", "completion_date": "2027-12", "has_results": false, "last_update_posted_date": "2026-08-07", "last_synced_at": "2026-09-18T00:31:50.236Z", "location_count": 7, "location_summary": "Huntsville, Alabama • Mobile, Alabama • Duarte, California + 4 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Duarte", "state": "California" }, { "city": "Glendale", "state": "California" }, { "city": "Rancho Mirage", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05640102" }, { "nct_id": "NCT03562637", "title": "Study of Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients With Globo H Positive TNBC", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Triple Negative Breast Cancer" ], "interventions": [ { "name": "adagloxad simolenin combined with OBI-821", "type": "BIOLOGICAL" }, { "name": "Globo H IHC Assay", "type": "DEVICE" }, { "name": "Standard of care treatment", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "DEVICE", "OTHER" ], "sponsor": "OBI Pharma, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 575, "start_date": "2018-12-05", "completion_date": "2027-12-30", "has_results": false, "last_update_posted_date": "2025-05-09", "last_synced_at": "2026-09-18T00:31:50.236Z", "location_count": 12, "location_summary": "La Jolla, California • San Diego, California • San Francisco, California + 9 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT03562637" }, { "nct_id": "NCT00891592", "title": "Umbilical Cord Blood Transplant for Hematological Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "CML", "AML", "MDS", "ALL", "NHL", "Multiple Myeloma", "Hodgkin's Disease" ], "interventions": [ { "name": "Ex Vivo CD3/CD28 costimulated Umbilical Cord Blood T cells", "type": "BIOLOGICAL" }, { "name": "Observation Arm", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "University of Pennsylvania", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "21 Years to 50 Years" }, "enrollment_count": 5, "start_date": "2009-01", "completion_date": "2016-05", "has_results": false, "last_update_posted_date": "2016-08-19", "last_synced_at": "2026-09-18T00:31:50.236Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00891592" }, { "nct_id": "NCT03316222", "title": "Study of GNS561 in Patients With Liver Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Hepatocellular Carcinoma", "Cholangiocarcinoma, Intrahepatic" ], "interventions": [ { "name": "GNS561", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genoscience Pharma", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2018-04-04", "completion_date": "2022-04-25", "has_results": false, "last_update_posted_date": "2022-05-02", "last_synced_at": "2026-09-18T00:31:50.236Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03316222" } ] }